Literature DB >> 35960353

Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population.

Natalia Aranza Zapata-Salazar1, David Emmanuel Kubelis-Lopez1, Mauricio Andres Salinas-Santander2, Celia Nohemi Sanchez-Dominguez3, Ana Cecilia Xolalpa-Rosales4, Marely Eugenia Gomez-Galindo4, Jorge Ocampo-Candiani5.   

Abstract

Vitiligo is the most common depigmenting disease characterized by achromic macules due to selective loss of melanocytes. The pathogenesis remains poorly elucidated, and multiple hypotheses exist regarding its pathogenesis. Evidence suggests that stress on melanocytes can result in activation of the immune system, and involvement of both activated cluster of differentiation (CD8+) cytotoxic and CD4+ T cells in the dysfunction, depigmentation, and apoptosis of melanocytes. Recent studies show that the interleukin 17 (IL-17) axis plays a central role in the pathogenesis of the disease. IL-17 is an important regulatory effector cytokine in this pathway. The aim of this study was to evaluate the association of IL-17A rs4711998 (-832A/G), IL-17A rs2275913 (-197G/A), and IL-17F rs763780 (7488A/G) with vitiligo in a Northeastern Mexican population. This was a case-control study and included 116 patients with vitiligo and 116 control subjects. Genotype characterization of IL-17A rs4711998 (-832A/G), IL-17A rs2275913 (-197G/A), and IL-17F rs763780 (7488A/G) was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. A p ≤ 0.05 was considered significant. It was observed that the combination of the genotypes GG/GA for IL-17F rs763780 (7488A/G) was associated with an increased risk for the development of vitiligo (OR 2.0943, 95% Cl 1.2375-3.5445, p = 0.0056). Regarding IL-17A rs4711998 (-832A/G) and IL-17A rs2275913 (-197G/A) genotyping, no association with vitiligo development was found. In conclusion, the SNP rs763780 in the IL-17F gene appears to be a risk factor for vitiligo development in this Mexican population and it may be useful in future studies, especially for the development of new therapies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Genetic variants; IL-17; Mexican population; Polymorphisms; Vitiligo

Year:  2022        PMID: 35960353     DOI: 10.1007/s00403-022-02382-8

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.033


  75 in total

Review 1.  Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.

Authors:  Ali Alikhan; Lesley M Felsten; Meaghan Daly; Vesna Petronic-Rosic
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

Review 2.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Comorbidities in vitiligo: comprehensive review.

Authors:  Aisha M Dahir; Simon F Thomsen
Journal:  Int J Dermatol       Date:  2018-05-28       Impact factor: 2.736

4.  Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients.

Authors:  Sue-Yun Hwang; Ho-Youn Kim
Journal:  Mol Cells       Date:  2005-04-30       Impact factor: 5.034

Review 5.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.

Authors:  David A Martin; Jennifer E Towne; Gregory Kricorian; Paul Klekotka; Johann E Gudjonsson; James G Krueger; Chris B Russell
Journal:  J Invest Dermatol       Date:  2012-06-07       Impact factor: 8.551

6.  Zusammenhang zwischen Vitiligo und wichtigen Komponenten des metabolischen Syndroms: eine systematische Übersicht und Metaanalyse.

Authors:  Pan Kang; Wei-Gang Zhang; Zhao-Hua Ji; Zhong-Jun Shao; Chun-Ying Li
Journal:  J Dtsch Dermatol Ges       Date:  2022-05       Impact factor: 5.584

Review 7.  The role of IL-17 in vitiligo: A review.

Authors:  Rasnik K Singh; Kristina M Lee; Ivan Vujkovic-Cvijin; Derya Ucmak; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Tina Bhutani; Maria Wei; Wilson Liao
Journal:  Autoimmun Rev       Date:  2016-01-21       Impact factor: 9.754

8.  Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort.

Authors:  Ana Batalla; Eliecer Coto; Leire González-Lara; Daniel González-Fernández; Juan Gómez; Tamara F Aranguren; Rubén Queiro; Jorge Santos-Juanes; Carlos López-Larrea; Pablo Coto-Segura
Journal:  J Dermatol Sci       Date:  2015-06-27       Impact factor: 4.563

9.  Interleukin-17 Gene Polymorphism (Rs2275913 G/A, Rs763780 C/T) in Rheumatoid arthritis:Meta-analysis Based on Ethnicity.

Authors:  Ming Shao; Wei Xu; Hui Yang; Yuting Chen; Xing Gao; Shanshan Xu; Shengqian Xu; Zongwen Shuai; Faming Pan
Journal:  Immunol Invest       Date:  2020-07-01       Impact factor: 3.657

Review 10.  Novel immunological and genetic factors associated with vitiligo: A review.

Authors:  Salvador Luis Said-Fernandez; Celia Nohemi Sanchez-Domínguez; Mauricio Andres Salinas-Santander; Herminia Guadalupe Martinez-Rodriguez; David Emmanuel Kubelis-Lopez; Natalia Aranza Zapata-Salazar; Osvaldo Tomas Vazquez-Martinez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-02-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.